Sacubitril / Valsartan: brand names and study card
Sacubitril / Valsartan — ARNI (neprilysin inhibitor + ARB). Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Sacubitril / Valsartan
Brands
Entresto
Class
ARNI (neprilysin inhibitor + ARB)
Mechanism
Sacubitril (via LBQ657) inhibits neprilysin; valsartan blocks the AT1 receptor.
Used for
Reduction of cardiovascular death and heart-failure hospitalization in adults with chronic heart failure; benefit is most evident when LVEF is below normal; Symptomatic heart failure with systemic left ventricular systolic dysfunction in children aged 1 year and older
Label date: 20260706 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Selectively blocks angiotensin II binding to AT1 receptors, inhibiting its vasoconstrictor and aldosterone-secreting effects.
On both cards: Common side effects — Hypotension; Hyperkalemia; Dizziness · Warnings — Hypotension · Interactions — Lithium
Only on the Valsartan card: Used for — Hypertension in adults and children aged 6 years and older; Reduction of heart-failure hospitalization in adults with NYHA class II–IV heart failure; Reduction of cardiovascular mortality in clinically stable adults with left ventricular failure or dysfunction after myocardial infarction · Common side effects — Headache; Fatigue · Warnings — Renal function and potassium changes; No aliskiren in diabetes · Interactions — Potassium-sparing diuretics / supplements; NSAIDs
Mechanism: Losartan selectively blocks angiotensin II binding at AT1 receptors; hydrochlorothiazide increases renal sodium and chloride excretion.
On both cards: Common side effects — Cough; Dizziness · Interactions — Lithium
Only on the Losartan / Hydrochlorothiazide card: Used for — Hypertension; this fixed-dose combination is not initial therapy except in selected severe cases where prompt control outweighs combination-initiation risk; Stroke-risk reduction in hypertension with left ventricular hypertrophy; the label reports evidence that this specific benefit does not apply to Black patients · Common side effects — Upper respiratory infection; Back pain · Warnings — Hypotension in volume-depleted patients; Renal function and electrolyte changes; Acute angle-closure glaucoma · Interactions — Potassium-raising agents; NSAIDs
Mechanism: Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II at its receptor.
On both cards: Common side effects — Hyperkalemia; Dizziness · Interactions — Lithium
Only on the Irbesartan card: Used for — Hypertension; Diabetic nephropathy in patients with type 2 diabetes, hypertension, elevated serum creatinine and proteinuria greater than 300 mg/day · Common side effects — Orthostatic dizziness; Orthostatic hypotension · Warnings — Hypotension in volume/salt depletion; Monitor renal function and potassium; Aliskiren contraindicated in diabetes · Interactions — Potassium-raising drugs; NSAIDs / COX-2 inhibitors
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Losartan: Drugs acting on the renin-angiotensin system can cause fetal injury and death; discontinue when pregnancy is detected.
Losartan / Hydrochlorothiazide: Fetal toxicity: drugs acting on the renin-angiotensin system can injure or kill the developing fetus; stop when pregnancy is detected.
Valsartan: Fetal toxicity: drugs acting on the renin-angiotensin system can injure or kill the developing fetus; stop when pregnancy is detected.
Capsera